ALX Oncology Holdings (ALXO) Earnings Analysis

ALX Oncology Holdings (ALXO) next reports earnings on 2026-08-11, consensus EPS -0.15 USD. Last quarter (2026-05-08) it missed with EPS -0.17 USD vs -0.15 USD est (-13.3%). It has beaten estimates in 2/7 recent quarters (29%). Trailing P/E -1.22.

Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades

When does ALXO next report earnings?

Next earnings date2026-08-11
Consensus EPS estimate-0.15 USD
Revenue estimaten/a

ALXO earnings history — beats and misses

Quarter (report date)EPS actualEPS est.SurpriseResult
2026-05-08-0.17 USD-0.15 USD-13.3%Miss
2026-02-27-0.42 USD-0.38 USD-10.5%Miss
2025-11-07-0.41 USD-0.37 USD-10.8%Miss
2025-08-12-0.49 USD-0.46 USD-6.5%Miss
2025-05-08-0.58 USD-0.47 USD-23.4%Miss
2025-03-06-0.55 USD-0.72 USD+23.6%Beat
2024-11-07-0.58 USD-0.78 USD+25.6%Beat

Beat rate: 2/7 (29%) over reported quarters with consensus data.

ALXO valuation and analyst view

Trailing P/E-1.22
Trailing EPS-1.63711 USD
Price / book0.72
Dividend yield0.00%
Market cap0.27B
Analyst consensusBuy (6 buy / 1 hold / 0 sell)
Avg price target4 USD

Related research pages

Frequently asked questions

When is ALX Oncology Holdings (ALXO)'s next earnings date?

ALX Oncology Holdings is next scheduled to report on 2026-08-11, with a consensus EPS estimate of -0.15 USD.

Did ALXO beat earnings last quarter?

In its 2026-05-08 report, ALXO posted EPS of -0.17 USD versus a -0.15 USD estimate — a miss of 13.3%.

What is ALXO's earnings track record?

Over the last 7 reported quarters with consensus data, ALXO beat estimates 2 times (29%).

What is ALXO's current P/E ratio and EPS?

ALXO trades at a trailing P/E of -1.22 on trailing EPS of -1.6371086709633553 USD.

What do analysts rate ALXO?

Analyst consensus is "Buy" across 7 ratings (0 strong buy, 6 buy, 1 hold, 0 sell, 0 strong sell). Average 12-month price target: 4 USD.